Skip to main content

Table 3 Items regarding CS2: Patient with non-functioning PANCREATIC NET, non-susceptible to surgery or to loco-regional treatment, and with Ki-67 < 10 %, ECOG ≤2: Treatment initiation with SSA, molecular targeted drugs or chemotherapy? [12, 36, 37, 63, 64]

From: Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program

  1. CS Clinical situation, SSAs Somatostatin analogs, NET Neuroendocrine tumor, C consensus, NC non-consensus, A Agreement, D Disagreement, I Indeterminate
  2. aOnly applies to statements with 2 rounds; participant % in median range: median range
  3. Shadowed boxes: non-consensus